Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERCEPT
NCT03283631Phase 1Terminated
- Sponsor
- Gary Archer (Duke University)
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EGFRvIII-CARs in glioblastoma (GBM) and Gliosarcoma (GS), sponsored by Gary Archer (Duke University). Primary endpoint: Maximum Tolerated Dose at 4 weeks. Started May 2018; status: terminated.
02
Drugs
EGFRvIII-CARs
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT03283631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283631.